Lou Gehrig's Disease Pipeline Grows as 75+ Pharma Companies Advance Novel ALS Therapies, Finds DelveInsight | Ionis Pharmaceuticals, MediciNova, Revalesio, QurAlis, MediciNova

DelveInsight's "Lou Gehrig's disease - Pipeline Insight, 2026" report provides comprehensive insights about 75+ companies developing several pipeline drugs in the Lou Gehrig's disease pipeline landscape. It covers the Lou Gehrig's disease pipeline drug profiles, including clinical and nonclinical stage products, along with therapeutics assessment by product type, stage, route of administration, and molecule type, and further highlights inactive pipeline products in this space.

Explore the latest breakthroughs in the Lou Gehrig's disease treatment landscape. Learn more about the evolving ALS pipeline today @ https://www.delveinsight.com/sample-request/amyotrophic-lateral-sclerosis-als-pipeline-insight

Key Takeaways from the Lou Gehrig's Disease Pipeline Report

• In April 13, 2026, Vector Y Therapeutics conducted a Phase 1/2, multicenter, open-label, ascending dose, uncontrolled, first-in-human study to evaluate the safety, tolerability, and effects on clinical and biomarker endpoints of intracisternal administration of Vtx-002 in participants with Amyotrophic Lateral Sclerosis.
• In April 08, 2026, argenx initiated a Phase 2a study to evaluate the safety of ARGX-119, and its impact on ALS disease outcomes, including muscle function, in adults with ALS.1
• In April 01, 2026, PhenoNet Inc. announced a Phase IIB, randomized, double-blind, placebo-controlled study to assess the effects of PHENOGENE-1A (oral inhalation via dry powder inhaler) in subjects with mild to moderate ALS disease.
• In Early 2026, a new Phase 3 clinical trial called PREVAiLS begins recruiting participants to test the drug pridopidine in people with early, rapidly progressive ALS.
• In September 2025, AL-S Pharma announced positive topline results from the Phase II clinical study evaluating AP-101, showing clinically meaningful changes in exploratory clinical outcome measures related to survival, non-invasive ventilation, disease-staging, and neurofilament biomarkers after 12 months of treatment.
• Lou Gehrig's disease, also known as Amyotrophic Lateral Sclerosis (ALS), is a progressive neurodegenerative disorder targeting motor neurons in the brain and spinal cord, leading to the loss of voluntary muscle control and paralysis.
• DelveInsight's Lou Gehrig's disease pipeline report depicts a robust space with 75+ active players working to develop 80+ pipeline therapies for treatment across multiple stages, from discovery through Phase III.
• Ionis Pharmaceuticals is advancing Ulefnersen, a Phase III antisense medicine designed to reduce mutant FUS protein production to prevent motor neuron loss.
• MediciNova's MN-166 is an oral small molecule glial attenuator currently in Phase II/III clinical evaluation for its potential to suppress neuroinflammation.
• Revalesio's RNS60 has received FDA Fast Track designation for its ability to activate intracellular signaling, increase mitochondrial function, and restore cellular homeostasis.
• QRL-201 by QurAlis Corporation is a first-in-class Phase I candidate aiming to restore STMN2 expression, a protein vital for neural repair that is typically depleted in ALS patients.
• ABBV-CLS-7262, developed by Calico Life Sciences and AbbVie, is being evaluated in a Phase II/III trial to assess safety and efficacy in patients with ALS.
• The leading Lou Gehrig's disease companies include Ionis Pharmaceuticals, MediciNova, Revalesio, QurAlis Corporation, Scholar Rock, 1ST Biotherapeutics, and AbbVie.
• Promising emerging therapies include Ulefnersen, MN-166, RNS60, QRL-201, and other undisclosed clinical-stage candidates spanning antisense oligonucleotides, small molecules, and gene therapies.

Download for updates and the latest revolution in ALS care @ https://www.delveinsight.com/sample-request/lou-gehrigs-disease-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=xpr

Lou Gehrig's Disease Emerging Drugs Profile
• Ulefnersen: Ionis Pharmaceuticals
Ulefnersen is a Phase III antisense medicine designed to target and reduce the production of mutant FUS protein. Because antisense-mediated reduction of mutant FUS protein in mouse models demonstrated the ability to prevent motor neuron loss, it is hypothesized that this treatment will reverse or prevent disease progression in FUS-ALS patients. Ionis Pharmaceuticals is currently evaluating this candidate in advanced clinical trials to address this specific genetic subtype of Lou Gehrig's disease.

• MN-166 (Ibudilast): MediciNova
MN-166 is an oral small molecule that acts as a glial attenuator to suppress neuroinflammation. It has been shown to be a toll-like receptor 4 (TLR4) functional antagonist, which contributes to its ability to attenuate chronic neuroinflammation associated with disease progression. Currently, MN-166 is being evaluated in Phase II/III clinical trials for the treatment of Lou Gehrig's disease, aiming to provide a meaningful disease-modifying effect.

• RNS60: Revalesio
RNS60 is being developed as a disease-modifying and potentially restorative treatment for neurological diseases. The drug activates intracellular signaling pathways to increase mitochondrial biogenesis and function while reducing inflammation. RNS60 is designed to safely protect neurons and oligodendrocytes and modulate immune cell activity to restore homeostasis. The FDA has granted RNS60 both Orphan Drug and Fast Track designations for ALS treatment.

For more information on the Lou Gehrig's Disease Emerging Drugs Profile, download DelveInsight's comprehensive Lou Gehrig's Disease Pipeline Insight report @https://www.delveinsight.com/sample-request/lou-gehrigs-disease-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=xpr

The Lou Gehrig's Disease Pipeline Report Provides

• Detailed insights about companies developing therapies for Lou Gehrig's disease, with aggregate therapies developed by each company.
• Different therapeutic candidates, segmented into early-stage, mid-stage, and late-stage of development for ALS treatment.
• Lou Gehrig's disease companies that are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• ALS drugs under development based on stage of development, route of administration, target receptor, monotherapy or combination therapy, mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company and company-academia), licensing agreements, and financing details for future advancement of the market.

Learn more about Lou Gehrig's disease drug opportunities in our comprehensive ALS pipeline report @ https://www.delveinsight.com/sample-request/lou-gehrigs-disease-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=xpr

Lou Gehrig's Disease Companies and Competitive Landscape

There are 75+ key companies, including Ionis Pharmaceuticals, MediciNova, Revalesio, QurAlis Corporation, Scholar Rock, 1ST Biotherapeutics, and AbbVie, developing therapies for Lou Gehrig's disease, with Ionis Pharmaceuticals having its drug candidate in the most advanced Phase III stage.

DelveInsight's Lou Gehrig's disease pipeline report provides the therapeutic assessment of the pipeline drugs by Route of Administration. Products have been categorized under various ROAs such as:

• Oral
• Intravenous
• Subcutaneous
• Parenteral
• Topical

Lou Gehrig's disease products have been categorized under various Molecule types such as:

• Recombinant fusion proteins
• Small molecule
• Monoclonal antibody
• Peptide
• Polymer
• Gene therapy

Discover the latest advancements in Lou Gehrig's disease treatment by visiting our website. Stay informed @ https://www.delveinsight.com/sample-request/lou-gehrigs-disease-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=xpr

Scope of the Lou Gehrig's Disease Pipeline Report
• Coverage: Global
• Lou Gehrig's Disease Companies: Ionis Pharmaceuticals, MediciNova, Revalesio, QurAlis Corporation, Scholar Rock, 1ST Biotherapeutics, AbbVie, and others.
• Lou Gehrig's Disease Therapies: Ulefnersen, MN-166, RNS60, QRL-201, and other undisclosed pipeline candidates.
• Lou Gehrig's Disease Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination.
• Lou Gehrig's Disease Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III.

Company Name: DelveInsight Business Research LLP
Contact Person: Arpit Anand
Email: info@delveinsight.com
Phone: +14699457679
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe, helping them stay ahead of the growth curve.

This release was published on openPR.